VBI VACCINES INC.
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | |
|---|---|---|---|---|---|---|
| Revenue | $395,960 | — | $10.8M | $7.7M | $15.4M | $18.1M |
| Operating income | −$13.2M | −$13.2M | — | — | — | — |
| Net income | −$13.9M | −$14.4M | −$5.5M | −$395,809 | −$3.1M | −$1.2M |
| Total assets | $8.4M | $13.7M | $2.2M | $13.3M | $16.1M | $19.7M |
| Total liabilities | $4.1M | $3.0M | $19.5M | $520,722 | $1.7M | $2.2M |
| Equity | $4.2M | $10.7M | −$17.2M | −$11.9M | $14.4M | $17.5M |
| EPS (diluted) | — | — | $0.01 | — | — | — |
| Shares out. | 20.0M | 6.6M | 5.8M | 5.8M | 5.8M | 5.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2015- Operating margin
- −3322.5%
- Net margin
- −3509.4%
- Return on equity
- −327.6%
- Return on assets
- −166.2%
- Return on capital (ROCE)
- −246.8%
- Liabilities / assets
- 49.3%
- Debt / equity
- 0.97×
- Book value / share
- $0.21
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2015- Altman Z″ (distress)
- -38.20distress
- Accruals / assets
- −34.3%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 14, 2013
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2006
- NT 10-Qmissed a reporting deadline ↗May 17, 2005
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2001
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2000
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Shareholder voteMay 9, 2016
- Regulation FD disclosureMay 9, 2016
- Other material eventApr 28, 2016
- Other material eventApr 14, 2016
- Other material eventMar 30, 2016
- Regulation FD disclosureMar 29, 2016
- Entered a material agreementMar 21, 2016
- Regulation FD disclosureMar 7, 2016
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13D/AARCH VENTURE FUND VI, L.P. - VBI VACCINES, INC. -- SCH 13G/A(#3E)Jul 25, 2023
- SC 13D/AARCH VENTURE FUND VI, L.P. / VBI VACCINES, INC. - SCHEDULE 13DA2May 6, 2020
- SC 13G/AFeb 12, 2020
- 4PRIMARY DOCUMENTSep 23, 2019
- SC 13G/AFeb 11, 2019
- SC 13GMay 29, 2018
- SC 13D/ACLARUS LIFESCIENCES I, L.P. VBI VACCINES INC. SCHEDULE 13DA - AMEND. #1Feb 9, 2018
- 4Apr 19, 2017
- 3Apr 19, 2017
- 4Apr 19, 2017
- 3Apr 19, 2017
- SC 13DSCHEDULE 13DMar 31, 2017
- SC 13D/AMar 9, 2017
- 4/AOWNERSHIP DOCUMENTMar 9, 2017
- SC 13G/AAMENDMENT NO. 2 TO SCHEDULE 13GFeb 10, 2017
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.